Table 2 Genomic profile in oligodendrogliomas in this study.
Genes | CNS WHO grade 2 (n = 28) | CNS WHO grade 3 (n = 46) | Total (n = 74) | ||
|---|---|---|---|---|---|
No of variant | |||||
Known variants | Novel variants | Known variants | Novel variants | Total | |
IDH mutation and 1p/19q co-deletion | 100% (74/74) | ||||
IDH1 | |||||
R132H | 92.9% (26/28) | 91.3% (42/46) | 91.9% (68/74) | ||
IDH2 | |||||
R172K | 3.6% (1/28) | 8.7% (4/46) | 6.8% (5/74) | ||
R172M | 3.6% (1/28) | 0 | 1.4% (1/74) | ||
CIC | |||||
Missense | 7.1% (2/28) | 7.1% (2/28) | 15.2% (7/46) | 10.9% (5/46) | 21.6% (16/74) |
Frameshift | 21.4% (6/28) | 0 | 21.7% (10/46) | 2.2% (1/46) | 23.0% (17/74) |
Multi-hit | 25.0% (7/28) | 3.6% (1/28) | 6.5% (3/46) | 8.7% (4/46) | 20.3% (15/74) |
Nonsense (Stop gain) | 3.6% (1/28) | 0 | 8.7% (4/46) | 0 | 6.8% (5/74) |
Intronic | 3.6% (1/28) | 0 | 4.3% (2/46) | 0 | 4.1% (3/74) |
Subtotal | 23.0% (17/74) | 4.1% (3/74) | 35.1% (26/74) | 13.5% (10/74) | 75.7% (56/74) |
FUBP1 | |||||
Nonsense (Stop gain) | 17.9% (5/28) | 0 | 13.0% (6/46) | 0 | 14.9% (11/74) |
Frameshift | 7.1% (2/28) | 3.6% (1/28) | 8.7% (4/46) | 2.2% (1/46) | 10.8% (8/74) |
Intronic | 14.3% (4/28) | 3.6% (1/28) | 4.3% (2/46) | 0 | 9.5% (7/74) |
Multi-hit | 3.6% (1/28) | 0 | 8.7% (4/46) | 0 | 6.8% (5/74) |
Missense | 3.6% (1/28) | 0 | 0 | 2.2% (1/46) | 2.7% (2/74) |
Subtotal | 17.6% (13/74) | 2.7% (2/74) | 23.0% (17/74) | 2.7% (2/74) | 45.9% (34/74) |
Either CIC and FUBP1 | 93.2% (69/74) | ||||
Both CIC and FUBP1 | 13.5% (10/74) | 16.2% (12/74) | 30.0% (22/74) | ||
TERT promoter | 100% (74/74) | ||||
C228T | 71.4% (20/28) | 65.2% (30/46) | 67.6% (50/74) | ||
C250T | 28.6% (8/28) | 34.8% (16/46) | 32.4% (24/74) | ||
MGMT promoter methylated | 100% (28/28) | 93.5% (43/46) | 95.9% (71/74) | ||
TP53 | 4.3% (2/46) | 2.7% (2/74) | |||
